Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Slayback Exclusivity On Taytulla Does Not Bar Rival ANDA Product
US-Based Player Received Approval With CGT Designation
Feb 05 2021
•
By
Dean Rudge
“CGT exclusivity is not applied retrospectively," Slayback told Generics Bulletin • Source: Shutterstock
More from Generics
More from Products